Samsung Biologics Co.,Ltd. (KRX:207940)
1,023,000
-11,000 (-1.06%)
Apr 16, 2025, 3:30 PM KST
Samsung Biologics Revenue
In the year 2024, Samsung Biologics had annual revenue of 4.55T KRW with 23.08% growth. Samsung Biologics had revenue of 1.26T in the quarter ending December 31, 2024, with 17.04% growth.
Revenue
4,547.32B
Revenue Growth
+23.08%
P/S Ratio
16.01
Revenue / Employee
953.32M
Employees
4,770
Market Cap
72.81T
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,547.32B | 852.73B | 23.08% |
Dec 31, 2023 | 3,694.59B | 693.29B | 23.10% |
Dec 31, 2022 | 3,001.30B | 1,433.29B | 91.41% |
Dec 31, 2021 | 1,568.01B | 403.23B | 34.62% |
Dec 31, 2020 | 1,164.78B | 463.19B | 66.02% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Celltrion | 3,557.30B |
ALTEOGEN | 102.85B |
Yuhan | 2,067.79B |
SK Biopharmaceuticals | 547.60B |
HLB Co., Ltd. | 68.13B |
LigaChem Biosciences | 125.90B |
PharmaResearch | 350.12B |
Peptron | 3.15B |